Coherus Oncology (CHRS) Convertible Debt (2016 - 2025)

Coherus Oncology (CHRS) has 10 years of Convertible Debt data on file, last reported at $228.6 million in Q1 2025.

• For the quarter ending Q1 2025, Convertible Debt rose 0.59% year-over-year to $228.6 million; the trailing twelve-month figure through Mar 2025 stood at $228.6 million (up 0.59% YoY), and the FY2024 full-year result was $228.2 million, up 0.59% from the prior year.
• Convertible Debt steadied at $228.6 million in Q1 2025, from $228.2 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $332.8 million in Q4 2021 to a low of $223.3 million in Q1 2021.
• A 5-year average of $232.3 million and a median of $226.2 million in 2023 frame the typical range for Convertible Debt.
• Across the five-year window, Convertible Debt surged 316.56% in 2021 and plunged 32.21% in 2022, its largest moves.
• Tracing CHRS's Convertible Debt over 5 years: stood at $332.8 million in 2021, then sank by 32.21% to $225.6 million in 2022, then advanced by 0.58% to $226.9 million in 2023, then grew by 0.59% to $228.2 million in 2024, then rose by 0.15% to $228.6 million in 2025.
• Business Quant data shows CHRS's Convertible Debt at $228.6 million in Q1 2025, $228.2 million in Q4 2024, and $227.9 million in Q3 2024.